Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
64 participants
INTERVENTIONAL
2011-02-28
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease
NCT00552409
Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
NCT00427037
Study of Vitamin D3 Supplementation in Patients With Chronic Kidney Disease
NCT00893451
Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease
NCT00511225
Cholecalciferol Supplementation Effect on Parathyroid Hormone in Hemodialysis Patients
NCT03648528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cholecalciferol
Cholecalciferol
3 tablets of 1000 IU daily for 26 weeks
Placebo
Placebo
3 tablets of 1000 IU daily for 26 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cholecalciferol
3 tablets of 1000 IU daily for 26 weeks
Placebo
3 tablets of 1000 IU daily for 26 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cancer
* Inability to give informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regional Hospital Holstebro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erling Bjerregaard Pedersen
DMSc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erling B Pedersen, M.D., M.Sci.
Role: PRINCIPAL_INVESTIGATOR
Departments of Medical Research and Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Departments of Medical Research and Medicine, Holstebro Hospital
Holstebro, Holstebro, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mose FH, Vase H, Larsen T, Kancir AS, Kosierkiewic R, Jonczy B, Hansen AB, Oczachowska-Kulik AE, Thomsen IM, Bech JN, Pedersen EB. Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial. BMC Nephrol. 2014 Mar 24;15:50. doi: 10.1186/1471-2369-15-50.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EBP-TL-2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.